Mark Wildgust has spent more than 20 years in the pharmaceutical industry working primarily in oncology, hematology and virology. He completed his undergraduate degree in Biological Sciences at the University of Plymouth, UK, and his PhD in Trace Metal Toxicology at the University of Manchester, UK. He then spent a short time as a post-doctoral researcher at the University of Maryland in the United States. After leaving academia, Mark worked for Bristol Myers Squibb and Pfizer before joining the Janssen Pharmaceutical Companies of Johnson & Johnson. Mark has now been with Janssen for 15 years.
During Mark’s career, he has predominantly spent time in medical affairs leading and supporting the medical strategy for a variety of compounds, including the launch of many blockbuster therapies like IMBRUVICA® and DARZALEX®. Currently, Mark serves as the Vice President of Oncology Global Medical Affairs, Janssen, where he leads a team of scientists and physicians supporting the development of new oncology and hematology therapies. This robust portfolio includes breakthrough therapies for lung cancer, hematologic malignancies, prostate cancer and bladder cancer, and spans novel mechanisms, CAR-Ts and bispecific antibodies. Mark is a 2018 PharmaVOICE 100 awardee, recognized as a Change Agent in Global Medical Affairs and a leading voice in shaping this important function in evidence generation and evidence communications.